CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 82 enrolled
Drug / intervention
LY3484356 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04840888
NCT04840888Phase 1Completed
CompareCT.gov

Evaluation of the Effect of Food, Omeprazole, Itraconazole, and Carbamazepine on the Pharmacokinetics of LY3484356 in Healthy Females of Non-Child-Bearing Potential

Eli Lilly and Company·interventional·Posted Apr 12, 2021·Updated Dec 11, 2025

In Brief

A Phase 1 clinical trial evaluating LY3484356, Omeprazole, and 3 other interventions for Healthy. Completed, enrolled 82 participants across 2 sites.

Detailed Summary

The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are healthy females of non-childbearing potential. The study will also evaluate the tolerability and safety of LY3484356 by collecting the information about any side effects that may occur. The participant's involvement with the study will last approximately 27 days, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedApr 12, 2021
Enrollment StartApr 26, 2021
Primary CompletionApr 12, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 5.2 years ago

Interventions

LY3484356drug

Administered orally.

Omeprazoledrug

Administered orally.

Itraconazoledrug

Administered orally.

Carbamazepinedrug

Administered orally.

Midazolamdrug

Administered orally.